Literature DB >> 31292797

Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?

Alessandro Vaisfeld1,2, Martina Calicchia2, Maria Grazia Pomponi1, Emanuela Lucci-Cordisco1,2, Luca Reggiani-Bonetti3, Maurizio Genuardi4,5.   

Abstract

Muir-Torre syndrome (MTS) is clinically characterized by the occurrence of skin, usually sebaceous, and visceral tumors in the same individual. The most common underlying mechanism is a constitutional defect of the mismatch repair (MMR) genes that cause Lynch syndrome (LS). Herewithin we report on a 76 years-old male patient heterozygous for a pathogenic MSH2 missense substitution who presented with a striking cutaneous phenotype in the absence of typical LS visceral tumors. The patient developed 20 skin tumors, including sebaceous adenomas/carcinomas and keratoacanthomas. Two skin tumors showed immunohistochemical loss of MSH2 and MSH6 expression. There was no apparent family history of neoplasia. Based on the variable involvement of the skin and internal organs, we suggest that the definition of tumor associations that are often observed as variants of inherited tumor syndromes, such as MTS, should be guided by the underlying molecular bases. In addition, the presence of multiple sebaceous tumors, especially if showing MMR deficiency, appears to be a very strong indicator of a constitutional MMR gene defect. The reasons underlying the high phenotypic variability of cutaneous phenotypes associated with constitutional MMR defects are yet to be determined.

Entities:  

Keywords:  Genetic test; Immunohistochemistry; Microsatellite instability; Mismatch repair; Molecular diagnosis

Mesh:

Substances:

Year:  2019        PMID: 31292797     DOI: 10.1007/s10689-019-00139-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  34 in total

Review 1.  Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.

Authors:  G Ponti; M Manfredini; A Tomasi; G Pellacani
Journal:  Gene       Date:  2015-07-02       Impact factor: 3.688

2.  Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.

Authors:  Megan N Landis; Carrie L Davis; Gary A Bellus; Stephen E Wolverton
Journal:  J Am Acad Dermatol       Date:  2011-05-06       Impact factor: 11.527

Review 3.  Muir-Torre syndrome.

Authors:  Feriyl Bhaijee; Alexandra S Brown
Journal:  Arch Pathol Lab Med       Date:  2014-12       Impact factor: 5.534

Review 4.  Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome.

Authors:  P R Cohen; S R Kohn; R Kurzrock
Journal:  Am J Med       Date:  1991-05       Impact factor: 4.965

5.  The frequency of Muir-Torre syndrome among Lynch syndrome families.

Authors:  Christopher D South; Heather Hampel; Ilene Comeras; Judith A Westman; Wendy L Frankel; Albert de la Chapelle
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

6.  Sebaceous carcinoma of the face following irradiation.

Authors:  I C Hood; A H Qizilbash; S S Salama; J E Young; S D Archibald
Journal:  Am J Dermatopathol       Date:  1986-12       Impact factor: 1.533

7.  Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.

Authors:  Chad J Jessup; Mark Redston; Erin Tilton; Julie D R Reimann
Journal:  Hum Pathol       Date:  2015-10-31       Impact factor: 3.466

8.  Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.

Authors:  Mev Dominguez-Valentin; Patrick Joost; Christina Therkildsen; Mats Jonsson; Eva Rambech; Mef Nilbert
Journal:  BMC Urol       Date:  2016-03-24       Impact factor: 2.264

9.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.

Authors:  Jeffrey P North; Justin Golovato; Charles J Vaske; J Zachary Sanborn; Andrew Nguyen; Wei Wu; Benjamin Goode; Meredith Stevers; Kevin McMullen; Bethany E Perez White; Eric A Collisson; Michele Bloomer; David A Solomon; Stephen C Benz; Raymond J Cho
Journal:  Nat Commun       Date:  2018-05-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.